This week's licensing deal between Onconova Therapeutics and Baxter international — worth up to $565 million for Onconova if its meets certain product development and regulatory approval milestones — is also proving a financial boost for Temple University. Kenneth Blank, senior vice provost for research and graduate education at Temple, said the deal could push Temple into the rankings of the top 30 colleges and universities nationally for tech licensing and commercialization revenue.